1.08
-0.01(-0.92%)
Currency In USD
| Previous Close | 1.09 |
| Open | 1.11 |
| Day High | 1.11 |
| Day Low | 1.06 |
| 52-Week High | 2.17 |
| 52-Week Low | 0.28 |
| Volume | 1.07M |
| Average Volume | 3.4M |
| Market Cap | 392.47M |
| PE | -3.37 |
| EPS | -0.32 |
| Moving Average 50 Days | 1.1 |
| Moving Average 200 Days | 0.77 |
| Change | -0.01 |
If you invested $1000 in Lexicon Pharmaceuticals, Inc. (LXRX) 10 years ago, it would be worth $85.78 as of September 09, 2025 at a share price of $1.08. Whereas If you bought $1000 worth of Lexicon Pharmaceuticals, Inc. (LXRX) shares 5 years ago, it would be worth $675 as of September 09, 2025 at a share price of $1.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
GlobeNewswire Inc.
Yesterday at 12:30 PM GMT
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA fee
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
GlobeNewswire Inc.
Sep 04, 2025 12:30 PM GMT
THE WOODLANDS, Texas, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Company will present new data demonstrating the reduction of neuropathic pain by pilavapadin in preclinical models of che
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
GlobeNewswire Inc.
Sep 03, 2025 12:30 PM GMT
THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP), des